Ernexa Therapeutics Inc. Proceeds from Long-Term Debt Issued
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Long-Term Debt Issued of $3.13 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2021-03-11
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $500.00K.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for the quarter ending 2020-09-30 was $1.00M.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for the quarter ending 2018-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for the quarter ending 2016-12-31 was $388.00K, a 64.70% decline year-over-year.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for fiscal 2020 was $3.13M.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for fiscal 2018 was $4.00M, a 7900.00% increase from fiscal 2017.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for fiscal 2017 was $50.00K, a 98.00% decline from fiscal 2016.
- Ernexa Therapeutics Inc. proceeds from issuance of long-term debt for fiscal 2016 was $2.50M, a 62.86% decline from fiscal 2015.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2020-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.50M derived: sum of 2 quarters · filed 2021-03-11 | $3.13M 10-K · filed 2021-03-11 | |
| 2020-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $2.63M 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | $1.63M 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $4.00M 10-K · filed 2020-03-19 | ||
| 2018-09-30 | $4.00M 10-Q · filed 2019-11-01 | |||
| 2017-12-31 | $50.00K 10-K · filed 2019-03-22 | |||
| 2016-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $388.00K derived: sum of 2 quarters · filed 2018-03-09 | $388.00K derived: sum of 3 quarters · filed 2018-03-09 | $2.50M 10-K · filed 2018-03-09 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $2.11M 10-Q · filed 2017-11-08 | $3.21M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $2.11M 10-Q · filed 2017-08-04 | $3.21M derived: sum of 3 quarters · filed 2017-08-04 | $4.28M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | $2.11M 10-Q · filed 2017-05-04 | $3.21M derived: sum of 2 quarters · filed 2017-05-04 | $4.28M derived: sum of 3 quarters · filed 2017-05-04 | $8.78M derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $2.16M derived: sum of 2 quarters · filed 2017-03-09 | $6.66M derived: sum of 3 quarters · filed 2017-03-09 | $6.74M 10-K · filed 2017-03-09 |
| 2015-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.56M derived: sum of 2 quarters · filed 2016-11-09 | $5.64M 10-Q · filed 2016-11-09 | $7.37M derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $4.57M 10-Q · filed 2016-08-04 | $6.30M derived: sum of 3 quarters · filed 2016-08-04 | $7.60M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $74.00K 10-Q · filed 2016-05-09 | $1.80M derived: sum of 2 quarters · filed 2016-05-09 | $3.10M derived: sum of 3 quarters · filed 2016-05-09 | |
| 2014-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $3.03M derived: sum of 2 quarters · filed 2016-03-15 | $6.05M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $4.32M 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | $3.02M 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |